Asia Pacific
Refine Search
Pharmaceutical
Japanese drug major Shionogi has completed its analysis of the Phase IIa part of a Phase II/III clinical trial of S-217622, an orally administered antiviral drug for COVID-19, and presented the results today. 7 February 2022
Pharmaceutical
In the third Japanese financial quarter, Takeda Pharmaceutical delivered year-to-date revenues of 2,700 billion yen ($23.5 billion), an increase of 11% on the same period from last year. 3 February 2022
Pharmaceutical
Tokyo-based drugmaker Kyowa Kirin has submitted for Japanese approval for Mitomycin-C (mitomycin) as a topical ophthalmic drug for use in glaucoma surgery. 31 January 2022
Pharmaceutical
Japanese drug major Shionogi edged up 2.4% to 6,464 yen this morning, as it presented the results up to day six of the Phase IIa part of a Phase II/III clinical trial of S-217622, an orally administered antiviral drug for COVID-19. 31 January 2022
Pharmaceutical
Trade group Medicines Australia has called for the country’s government to deliver a plan that shortens the time that patients wait for access to the latest innovative treatments and vaccines. 28 January 2022
Biotechnology
UK drugmaker GlaxoSmithKline and its US partner Vir Biotechnology have taken action to boost production of their antibody-based COVID-19 faced with huge demand. 24 January 2022
Biotechnology
Belgium biopharma UCB today announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted marketing authorization for Bimzelx (bimekizumab) for the treatment of plaque psoriasis, generalized pustular psoriasis and psoriatic erythroderma in patients who are not sufficiently responding to existing treatments. 24 January 2022
Biotechnology
The Japanese subsidiary of New York’s Bristol Myers Squibb has secured approval for its CAR T-cell immunotherapy Abecma (idecabtagene vicleucel). 21 January 2022
Pharmaceutical
The equity research team at US financial services firm Morningstar has published the Annual Drug Pipeline report, which looks at the large-cap biopharma groups and their position in the market. 20 January 2022
Pharmaceutical
Japanese drug major Daiichi Sankyo edged up 1.6% to 2,608 yen after it revealed it has entered into an agreement with Cosette Pharmaceuticals, whereby it divested and Cosette acquired rights for manufacturing, commercialization, and certain other rights for the following products in the USA: 20 January 2022
Biotechnology
The Japanese subsidiary of Swiss biotech Idorsia today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved Pivlaz (clazosentan sodium) 150mg. 20 January 2022
Biotechnology
Chinese biotech Hutchmed today announced that the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy designation (BTD) to HMPL-523, a novel, investigational spleen tyrosine kinase (Syk) inhibitor, for the treatment of chronic adult primary immune thrombocytopenia (ITP) patients who have received at least one prior therapy. 12 January 2022
Generics
China’s Pharmaron Beijing has acquired Aesica Pharmaceuticals (the Cramlington Site) from Swedish Contract Development and Manufacturing Organization (CDMO) Recipharm group. 10 January 2022
Biotechnology
Japanese pharma major Eisai has granting the exclusive rights for global research, development, manufacture and sale of the investigational anticancer agent H3B-8800 to a subsidiary of London-headquartered Roivant Sciences. 6 January 2022
Biotechnology
Chinese biotech BeiGene has announced that the China National Medical Products Administration (NMPA) has approved its anti-PD-1 antibody tislelizumab as a second- or third-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). 6 January 2022
Biotechnology
Shares of Swiss biotech Santhera Pharmaceuticals were up 15.4% at 1.50 Swiss francs by early afternoon, after it revealed an exclusive license agreement with China-based rare diseases specialist Sperogenix Therapeutics. 4 January 2022
Biotechnology
South Korean Celltrion Group’s shares edged up 1.8% to 200,000 Korean won in early trading on Monday, after it released results for its COVID-19 cocktail therapy candidates including neutralization data against the Omicron variant. 4 January 2022
Generics
Bangladeshi generics and active ingredients maker Beximco Pharmaceuticals today announced the launch of the world's first generic version of Pfizer’s COVID-19 treatment Paxlovid (nirmatrelvir and ritonavir tablets, co-packaged for oral use), which was granted emergency use authorization (EUA) by the US Food and Drug Administration on December 22, 2021. 30 December 2021
Biotechnology
Daiichi Sankyo’s shares edged up nearly 2% in early trading, after the Japanese pharma major released regulatory updates on two of its investigational products. 29 December 2021
Biotechnology
Shares of US drug developer Sutro Biopharma were up more than 8% at $15.77 by mid-morning, after the company announced an exclusive license agreement with Tasly Biopharmaceuticals, a holding subsidiary of Tasly Pharmaceutical Group, for the development and commercialization of STRO-002 in Greater China, consisting of mainland China, Hong Kong, Macau and Taiwan. 28 December 2021
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Zhongshan-based biopharma company Akeso will await the verdict of the Chinese medicines regulator on a penpulimab-based combo therapy. 22 November 2024
Pharmaceutical
Shanghai-based Zai Lab and New York’s Pfizer are to work together on the commercialization of Xacduro (sulbactam-durlobactam) in China. 22 November 2024
Biotechnology
Hong Kong-based Sino Biopharm has signed an equity investment and strategic collaboration agreement with LaNova Medicines, advancing its oncology focus. 22 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biosimilars
Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the European Commission (EC) for their Opuviz 40mg/mL solution for injection in a vial, a biosimilar referencing Regeneron and Bayer’s Eylea (aflibercept). 18 November 2024
Biotechnology
Shanghai-based Junshi Biosciences has received UK regulatory approval for Loqtorzi (toripalimab) in nasopharyngeal carcinoma (NPC) and esophageal squamous cell carcinoma (ESCC). 18 November 2024
Biotechnology
Chinese biotech Keymed Biosciences has entered an exclusive licensing agreement with Platina Medicines for its bispecific antibody candidate, CM336. 18 November 2024
Pharmaceutical
In yet another sign of the mounting interest in radiopharmaceuticals, Tongrui Biopharma, a Chinese innovator in this area, has announced the completion of a $100 million series A+ financing round. 18 November 2024
Biotechnology
Shanghai-based biopharma Zai Lab has announced the pricing of its underwritten public offering at $25.50 per share, aiming to raise around $200 million. 15 November 2024
Biosimilars
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. 15 November 2024
Biotechnology
Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based clinical-stage biotech LaNova Medicines, bringing the US pharma giant into the newly attractive PD-1/VEGF bispecific antibody space. 15 November 2024
Biotechnology
Japanese drugmaker Nippon Shinyaku and USA-based Atsena Therapeutics have entered into an exclusive license agreement for the commercialization of ATSN-101 in the USA and Japan for advancing Atsena’s first- in-class, investigational gene therapy ATSN-101 for Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1). 13 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze